Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children

Basit Öğe Kaydı
dc.contributor.authorAksoylar, S
dc.contributor.authorCetingul, N
dc.contributor.authorKantar, M
dc.contributor.authorKarapinar, D
dc.contributor.authorKavakli, K
dc.contributor.authorKansoy, S
dc.date.accessioned2019-10-27T19:05:12Z
dc.date.available2019-10-27T19:05:12Z
dc.date.issued2004
dc.departmentEge Üniversitesien_US
dc.description.abstractThe aim of this study was to evaluate the efficacy and safety of meropenum plus amikacin compared with piperacillin-tazobactam plus netilmicin for initial empirical antibiotic treatment of high-fisk febrile neutropenia in children with cancer. Patients with hematologic malignancy (leukemia or stage III/IV non-Hodgkin lymphoma) who presented with fever and neutrepenia (ANC < 500/mm(3)) and patients with solid tumors who presented with fever and severe. neutropenia (ANC < 100/mm(3)) were considered to be at high risk and eligible,for this study. In this prospective study, 33 patients with 50 febrile neutropenic episodes received iv meropenem (20 mg/kg every 8 h) plus amikacin (15 mg/kg/d in 2 divided doses) (in 31 episodes) or piperacillin/tazobactam (100 mg/4 mg/kg every 8 h) plus netilmicin (7 mg/kg every 24 h) (in 19 episodes). Clinical response was determined at 72 h and at completion of the therapy. The groups were comparable in terms of age, sex, initial ANC, use of growth factors, and classification of the infections. An infection was documented microbiologically in 12 episodes (39%) in the meropenem plus amikacin group and in 8 episodes (42%) in the piperacillin/tazobactam plus netilmicin group. Of the 22 microbiological isolates, 37% were gram-positives, 45 % were gram-negatives, and 18 % were fungi. Most of the clinically documented infections were of lower respiratory tract, gastrointestinal mucosa, or urinary tract origin. The mean duration of neutropenia was 9 days in both groups. Fever persisted for 1-30 days (mean 3 vs. 5 days). The success rate with initial empiric therapy was 52 % in the meropenem plus amikacin and 42 % in the piperacillin/tazobactam plus netmicin g-roup, respectively (p =.5). Total success rate (with or without modification) was 97 % vs. 90 % in the episodes. Three patients died due to infection (I vs. 2 patients). No major adverse effects were, observed in each group. Empirical therapy with meropenem plus amikacin or piperacillin/azobactam plus netilmicin effective and safe in pediatric cancer patients.en_US
dc.identifier.doi10.1080/08880010490277321en_US
dc.identifier.endpage123en_US
dc.identifier.issn0888-0018
dc.identifier.issn1521-0669
dc.identifier.issue2en_US
dc.identifier.pmid15160510en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage115en_US
dc.identifier.urihttps://doi.org/10.1080/08880010490277321
dc.identifier.urihttps://hdl.handle.net/11454/38269
dc.identifier.volume21en_US
dc.identifier.wosWOS:000220109800004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofPediatric Hematology and Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectaminoglycosideen_US
dc.subjectcancer childrenen_US
dc.subjectfibrile neutropeniaen_US
dc.subjecthigh-risken_US
dc.subjectmeropenemen_US
dc.subjectpiperacillin/tazobactamen_US
dc.titleMeropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in childrenen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu